Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Endothelial Cell Heterogeneity

(2013) W. C. Aird   Cold Spring Harbor Perspectives in Medicine

Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy

(2013) Alexander M. Lesokhin et al.   OncoImmunology

Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma

(2013) Stefanie Regine Dannenmann et al.   OncoImmunology

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation

(2012) James W. Hodge et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

(2012) I. Verbrugge et al.   CANCER RESEARCH

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Using antibodies to target cancer therapeutics

(2012) David M Goldenberg et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

(2012) Mélanie Bruchard et al.   NATURE MEDICINE

Immune modulation by molecular cancer targets and targeted therapies

(2012) Claudia Rossig   OncoImmunology

Targeting the right regulatory T-cell population for tumor immunotherapy

(2012) Vivian L. Weiss et al.   OncoImmunology

Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells

(2012) José Medina-Echeverz et al.   OncoImmunology

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer

(2012) Anna R. Kwilas   Frontiers in Oncology

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

(2011) Viktor Umansky et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4

(2011) Y. Zhu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice

(2010) M. Gonzalez-Aparicio et al.   GUT

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice

(2010) Mitomu Kioi et al.   JOURNAL OF CLINICAL INVESTIGATION

Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells

(2010) J. Medina-Echeverz et al.   JOURNAL OF IMMUNOLOGY

Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms

(2010) Zvi G Fridlender et al.   MOLECULAR THERAPY

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects

(2008) Mala Chakraborty et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

(2008) R. J. Lechleider et al.   CLINICAL CANCER RESEARCH

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

(2008) Andrea Molckovsky et al.   Journal of Hematology & Oncology

Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era

(2008) F. Petrelli et al.   ONCOLOGIST